Entero Therapeutics (Entero Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Entero Therapeutics 3-Year Revenue Growth Rate?

Entero Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Entero Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Entero Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entero Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entero Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Entero Therapeutics's 3-Year Revenue Growth Rate falls into.

Entero Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Entero Therapeutics (NAS:ENTO) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Entero Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics (Entero Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (NAS:ENTO) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Executives

James Sapirstein	director, officer: President and CEO	1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano	officer: Chief Financial Officer	271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman	director	777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski	director	1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell	director	C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm	director	1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes	director	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington	officer: CHIEF MEDICAL OFFICER	25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman	officer: CHIEF FINANCIAL OFFICER	760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr.	10 percent owner	C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor	director, officer: President and CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc	10 percent owner	PO BOX 2422, WESTPORT CT 06880